AR074196A1 - Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas - Google Patents
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicasInfo
- Publication number
- AR074196A1 AR074196A1 ARP090104435A ARP090104435A AR074196A1 AR 074196 A1 AR074196 A1 AR 074196A1 AR P090104435 A ARP090104435 A AR P090104435A AR P090104435 A ARP090104435 A AR P090104435A AR 074196 A1 AR074196 A1 AR 074196A1
- Authority
- AR
- Argentina
- Prior art keywords
- physiological conditions
- under physiological
- reduce
- large macromolecule
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
Método para reducir la agregacion e inhibir la floculacion de una macromolécula grande, tal como una proteína, bajo condiciones fisiologicas, mediante la adicion de 5% a 20% de polivinilpirrolidona (PVP) con un rango de peso molecular de 2000 a 54.000 daltons. Método para reducir al mínimo la inflamacion en el sitio de inyeccion durante la administracion subcutánea de una macromolécula grande. Formulaciones farmacéuticas para la administracion subcutánea de una macromolécula grande, y métodos para tratar un cáncer CD20 positivo o una enfermedad autoinmune, que comprende administrar un anticuerpo anti-CD20 humanizado en una formulacion farmacéutica de la solicitud. Método de diálisis in vitro para evaluar la capacidad de un excipiente de reducir la agregacion de un anticuerpo u otra macromolécula grande bajo condiciones fisiologicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11543908P | 2008-11-17 | 2008-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074196A1 true AR074196A1 (es) | 2010-12-29 |
Family
ID=42170394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104435A AR074196A1 (es) | 2008-11-17 | 2009-11-16 | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20110300135A1 (es) |
| EP (1) | EP2358394A4 (es) |
| JP (2) | JP2012509270A (es) |
| KR (2) | KR20140133588A (es) |
| CN (2) | CN103705930A (es) |
| AR (1) | AR074196A1 (es) |
| AU (1) | AU2009313756B2 (es) |
| BR (1) | BRPI0916042A2 (es) |
| CA (1) | CA2742990A1 (es) |
| CL (1) | CL2011001131A1 (es) |
| HK (1) | HK1164750A1 (es) |
| IL (1) | IL212532A0 (es) |
| MX (1) | MX2011005056A (es) |
| PE (2) | PE20120204A1 (es) |
| RU (1) | RU2011124527A (es) |
| TW (1) | TW201021831A (es) |
| WO (1) | WO2010057109A1 (es) |
| ZA (1) | ZA201102998B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2348051B1 (en) | 2003-11-05 | 2018-12-19 | Roche Glycart AG | CD20 antibodies with increased fc receptor binding affinity and effector function |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| SI2946765T1 (sl) | 2014-05-23 | 2016-11-30 | Ares Trading S.A. | Tekoči farmacevtski sestavek |
| TWI654202B (zh) * | 2014-05-27 | 2019-03-21 | 中央研究院 | 增進抗體功效之通用糖型之組合物及方法 |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3288981A1 (en) * | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| US11654112B2 (en) | 2016-11-22 | 2023-05-23 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| WO2020160323A2 (en) | 2019-01-31 | 2020-08-06 | Elektrofi, Inc. | Particle formation and morphology |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| US20220251627A1 (en) * | 2019-06-28 | 2022-08-11 | Zymo Research Corporation | Compositions for the stabilization of cell-free nucleic acids and methods thereof |
| JP2022547546A (ja) | 2019-09-13 | 2022-11-14 | エレクトロフィ，インコーポレイテッド | 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法 |
| CN116370408A (zh) * | 2020-06-17 | 2023-07-04 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂 |
| EP4508086A1 (en) | 2022-04-13 | 2025-02-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| DE602004020061D1 (de) * | 2003-04-09 | 2009-04-30 | Genentech Inc | Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer |
| US20060067930A1 (en) * | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| MX2009013656A (es) * | 2007-06-12 | 2010-03-30 | Wyeth Llc | Composiciones terapeuticas anti-cd20 y metodos. |
-
2009
- 2009-11-16 AU AU2009313756A patent/AU2009313756B2/en not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064613 patent/WO2010057109A1/en active Application Filing
- 2009-11-16 EP EP09826921A patent/EP2358394A4/en not_active Withdrawn
- 2009-11-16 TW TW098138928A patent/TW201021831A/zh unknown
- 2009-11-16 MX MX2011005056A patent/MX2011005056A/es active IP Right Grant
- 2009-11-16 AR ARP090104435A patent/AR074196A1/es unknown
- 2009-11-16 CN CN201310481798.1A patent/CN103705930A/zh active Pending
- 2009-11-16 PE PE2011001039A patent/PE20120204A1/es not_active Application Discontinuation
- 2009-11-16 PE PE2014001174A patent/PE20142332A1/es not_active Application Discontinuation
- 2009-11-16 CA CA2742990A patent/CA2742990A1/en not_active Abandoned
- 2009-11-16 JP JP2011536561A patent/JP2012509270A/ja not_active Ceased
- 2009-11-16 BR BRPI0916042A patent/BRPI0916042A2/pt not_active IP Right Cessation
- 2009-11-16 RU RU2011124527/10A patent/RU2011124527A/ru not_active Application Discontinuation
- 2009-11-16 KR KR1020147027470A patent/KR20140133588A/ko not_active Application Discontinuation
- 2009-11-16 CN CN2009801546655A patent/CN102281902B/zh not_active Expired - Fee Related
- 2009-11-16 KR KR1020117011109A patent/KR20110097772A/ko not_active Application Discontinuation
-
2011
- 2011-04-20 ZA ZA2011/02998A patent/ZA201102998B/en unknown
- 2011-04-28 IL IL212532A patent/IL212532A0/en unknown
- 2011-05-13 US US13/107,082 patent/US20110300135A1/en not_active Abandoned
- 2011-05-16 CL CL2011001131A patent/CL2011001131A1/es unknown
-
2012
- 2012-06-14 HK HK12105796.1A patent/HK1164750A1/xx not_active IP Right Cessation
-
2013
- 2013-11-26 US US14/090,259 patent/US20140308270A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015061508A patent/JP2015157820A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140308270A1 (en) | 2014-10-16 |
| PE20142332A1 (es) | 2015-01-29 |
| EP2358394A1 (en) | 2011-08-24 |
| CL2011001131A1 (es) | 2012-02-03 |
| KR20140133588A (ko) | 2014-11-19 |
| WO2010057109A1 (en) | 2010-05-20 |
| US20110300135A1 (en) | 2011-12-08 |
| CN103705930A (zh) | 2014-04-09 |
| TW201021831A (en) | 2010-06-16 |
| CN102281902A (zh) | 2011-12-14 |
| EP2358394A4 (en) | 2013-03-06 |
| ZA201102998B (en) | 2013-06-26 |
| AU2009313756A1 (en) | 2010-05-20 |
| CA2742990A1 (en) | 2010-05-20 |
| JP2012509270A (ja) | 2012-04-19 |
| KR20110097772A (ko) | 2011-08-31 |
| CN102281902B (zh) | 2013-11-13 |
| MX2011005056A (es) | 2011-05-31 |
| AU2009313756B2 (en) | 2015-02-26 |
| PE20120204A1 (es) | 2012-03-03 |
| JP2015157820A (ja) | 2015-09-03 |
| IL212532A0 (en) | 2011-06-30 |
| BRPI0916042A2 (pt) | 2015-11-10 |
| RU2011124527A (ru) | 2012-12-27 |
| HK1164750A1 (en) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074196A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| Blakaj et al. | Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data | |
| CY1123597T1 (el) | Σκευασματα ινσουλινης για γρηγορη προσληψη | |
| EP2358395A4 (en) | METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS | |
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| IN2012DN00407A (es) | ||
| MX2013005341A (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| CO7151496A2 (es) | Agentes terapeúticos para administración subcutánea optimizados | |
| AU2019268085A1 (en) | Compound of glycosaminoglycan, preparation method and use thereof | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR078170A1 (es) | Metodos para el tratamiento de tumores cerebrales | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |